Main menu

Responsibility

James Campling
Scientific Adviser (Anti-infectives)
Base/Location: 
Walton Oaks, United Kingdom
NGO Partner: 
US Agency for International Development
Assignment Location: 
Bangkok, Thailand
Duration: 
July – October
Fellowship Title: 
Prevention Fellow
Fellow Biography: 

James joined Pfizer in 2006 as a graduate in the Clinical Research Group, setting up clinical trials.  From there he moved to the Medical Affairs team in 2010 where he started in a field-based medical role supporting the anti-infectives team (as well as completing a Masters in fungal disease) before taking up his present role.  Currently, James is responsible for maintaining compliance and providing medical and scientific support to the U.K. anti-infectives business by working closely with both internal and external customers. 

With support from USAID, Population Services International (PSI) and local partners are implementing a behavioral change communication program to prevent HIV, tuberculosis and malaria in the Greater Mekong sub region of Thailand.  Fellows will have the unique opportunity to assist PSI in the development of the “CAP-3D” project by assessing and developing information and communications technology (ICT) to reach those affected by HIV to encourage testing, counseling and an adherence regime. 

In 2014, James will start an assessment, define a strategy and work plan to build an awareness and behavior change campaign. James’ ability to organize, assimilate and communicate scientific information in an understandable manner will be of real value to his role in Thailand. He is passionate about this opportunity to utilize his skills and expertise to make a tangible and positive impact on people’s lives during his GHF experience.

By applying his time, effort and skills James hopes in turn to acquire a deeper understanding of the impact of HIV and AIDS.  He also hopes to further develop his strategic planning, communication and leadership skills by working in a different culture and embracing the challenges that this will no doubt present.

Since the inception of its HIV/AIDS program in 1986, the U.S. Agency for International Development (USAID) has funded over $6 billion in the fight against this pandemic - more than any other public or private organization. In order to translate this funding into action, USAID collaborates with a wide array of partners in developing countries including local companies and multi-national corporations. With effective coordination, these public-private partnerships can significantly expand quality HIV/AIDS prevention, care and treatment interventions.